{"filing":{"accession_number":"0001193125-26-341236","cik":"0000034956","ticker":"TENX","company_name":"TENAX THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d115761d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526341236/d115761d8k.htm"},"events":[{"id":26357,"run_id":23948,"accession_number":"0001193125-26-341236","anchor_item_number":"8.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company issued a press release announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103. Although the primary endpoint was not met (6-minute walk distance improvement), the disclosure of Phase 3 trial results—a major clinical milestone for a development-stage pharmaceutical company—constitutes a material event comparable to an earnings release in terms of investor significance. The results include detailed efficacy, safety, and biomarker data that would materially affect investor assessment of the drug candidate's viability and the company's regulatory path forward.","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27449,"accession_number":"0001193125-26-341236","item_number":"8.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company issued a press release announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103. Although the primary endpoint was not met (6-minute walk distance improvement), the disclosure of Phase 3 trial results—a major clinical milestone for a development-stage pharmaceutical company—constitutes a material event comparable to an earnings release in terms of investor significance. The results include detailed efficacy, safety, and biomarker data that would materially affect investor assessment of the drug candidate's viability and the company's regulatory path forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:20:37.864952+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27449,"accession_number":"0001193125-26-341236","item_number":"8.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company issued a press release announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103. Although the primary endpoint was not met (6-minute walk distance improvement), the disclosure of Phase 3 trial results—a major clinical milestone for a development-stage pharmaceutical company—constitutes a material event comparable to an earnings release in terms of investor significance. The results include detailed efficacy, safety, and biomarker data that would materially affect investor assessment of the drug candidate's viability and the company's regulatory path forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:20:37.864952+00:00","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-08-10"}]}